Allena Pharmaceuticals Inc.

(NASDAQ:ALNA) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.

Contact Information

Website: www.allenapharma.com
Email: info@allenapharma.com
Main Phone: +1 617 467-4577
Address: One Newton Executive Park
Address 2: Suite 202
State: MA
City / Town: Newton
Country: US
Postal Code: 02462

Issuer Information

Exchange: NGS
CEO: Louis Brenner
Employees: 41
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A